keyword
https://read.qxmd.com/read/38548807/real-time-analysis-of-osteoclast-resorption-and-fusion-dynamics-in-response-to-bone-resorption-inhibitors
#1
JOURNAL ARTICLE
Preety Panwar, Jacob Bastholm Olesen, Galia Blum, Jean-Marie Delaisse, Kent Søe, Dieter Brömme
Cathepsin K (CatK), an essential collagenase in osteoclasts (OCs), is a potential therapeutic target for the treatment of osteoporosis. Using live-cell imaging, we monitored the bone resorptive behaviour of OCs during dose-dependent inhibition of CatK by an ectosteric (Tanshinone IIA sulfonate) and an active site inhibitor (odanacatib). CatK inhibition caused drastic reductions in the overall resorption speed of OCs. At IC50 CatK-inhibitor concentration, OCs reduced about 40% of their trench-forming capacity and at fourfold IC50 concentrations, a > 95% reduction was observed...
March 28, 2024: Scientific Reports
https://read.qxmd.com/read/38462960/cathepsin-k-inhibition-alleviates-periodontal-bone-resorption-by-promoting-type-h-vessel-formation-through-pdgf-bb-pdgfr-%C3%AE-axis
#2
JOURNAL ARTICLE
Huan Zhou, Yi-Fan Zhang, Qian-Qian Zhang, Fen Liu, Jia-Yu Zhang, Yue Chen
OBJECTIVES: To explore the effects of cathepsin K (CTSK) inhibition on type H vessel formation and alveolar bone resorption within periodontitis. METHODS: Conditioned media derived from preosteoclasts pretreated with the CTSK inhibitor odanacatib (ODN), ODN supplemented small interfering RNA targeting PDGF-BB (si-PDGF-BB), or PBS were prepared, to assess their proangiogenic effects on endothelial cells (HUVECs). A series of angiogenic-related assays were conducted to evaluate HUVEC proliferation, migration, and tube formation abilities in vitro...
March 11, 2024: Oral Diseases
https://read.qxmd.com/read/38118338/interaction-mechanism-of-a-cysteine-protease-inhibitor-odanacatib-with-human-serum-albumin-in-vitro-and-bioinformatics-studies
#3
JOURNAL ARTICLE
Nurul Jannah Mohd Asngari, Khairul Azreena Bakar, Shevin Rizal Feroz, Fathilah Abdul Razak, Adyani Azizah Abd Halim
Odanacatib (ODN) is a selective cathepsin K inhibitor that acts as an anti-resorptive agent to treat osteoporosis. ODN is also found effective in reducing the effect of severe periodontitis. The interaction between ODN and human serum albumin (HSA) was investigated using spectroscopic, microscopic, and in silico approaches to characterize their binding. The fluorescence intensity of HSA increased upon the addition of increasing concentrations of ODN accompanied by blueshift in the fluorescence spectrum, which suggested hydrophobic formation around the microenvironment of the fluorophores upon ODN binding...
February 2024: Biophysical Chemistry
https://read.qxmd.com/read/37330581/cathepsin-k-inhibition-induces-raptor-destabilization-and-mitochondrial-dysfunction-via-syk-shp2-src-otub1-axis-mediated-signaling
#4
JOURNAL ARTICLE
Seung Un Seo, Seon Min Woo, Taeg Kyu Kwon
The Raptor signaling pathway is a critical point of intervention in the invasion and progression of cancer. The non-receptor tyrosine kinase Src-mediated phosphorylation of OTUB1-Y26 plays a critical role in Raptor stabilization, whereas cathepsin K inhibitor (odanacatib; ODN) and knockdown (siRNA) induce Raptor destabilization. However, the mechanisms involved in cathepsin K inhibition-induced OTUB1-Y26 phosphorylation in Raptor stabilization have not been yet elucidated. This study showed that cathepsin K inhibition activates SHP2, a tyrosine phosphatase, that dephosphorylates OTUB1 and destabilizes Raptor, whereas SHP2 deletion and pharmacological inhibition increase OTUB1-Y26 phosphorylation and Raptor expression...
June 17, 2023: Cell Death & Disease
https://read.qxmd.com/read/37169994/efficacy-and-safety-of-odanacatib-for-osteoporosis-treatment-a-systematic-review-and-meta-analysis
#5
REVIEW
Rongjin Chen, Changshun Chen, Bin Geng, Chenhui Yang, Hefang Xiao, Fei Yang, Hao Wang, Yayi Xia
PURPOSE: Osteoporosis is a metabolic bone disease that commonly results in middle-aged and elderly people following fractures. Odanacatib (ODN), a potential osteoporosis medication, was stopped in the Long-term Odanacatib Fracture Trial (LOFT) phase III study because it increased the risk of stroke. Herein, we conducted a systematic review and meta-analysis to further assess the efficacy and safety of ODN in osteoporosis treatment. METHODS: We searched the PubMed, EMBASE, Cochrane Library, and Web of Science, using the core search terms "osteoporosis" and "odanacatib...
May 11, 2023: Archives of Osteoporosis
https://read.qxmd.com/read/37162106/do-matrix-metalloproteinase-and-cathepsin-k-inhibitors-work-synergistically-to-reduce-dentin-erosion
#6
JOURNAL ARTICLE
Xiujiao Lin, Xinwen Tong, Hui Yang, Yiying Chen, Hao Yu
OBJECTIVES: To evaluate the effects of matrix metalloproteinase (MMP) and cathepsin K (catK) inhibitors on resistance to dentin erosion. METHODOLOGY: A total of 96 dentin specimens (3×3×2 mm) were prepared and randomly assigned into four groups (n=24): deionized water (DW); 1 µM odanacatib (ODN, catK inhibitor); 1 mM 1,10-phenanthroline (PHEN, MMP inhibitor); and 1 µM odanacatib + 1 mM 1,10-phenanthroline (COM). Each group was further divided into two subgroups for the application of treatment solutions before (PRE) and after erosive challenges (POST)...
2023: Journal of Applied Oral Science: Revista FOB
https://read.qxmd.com/read/36852432/an-approach-combining-deep-learning-and-molecule-docking-for-drug-discovery-of-cathepsin-l
#7
JOURNAL ARTICLE
Qi Li, Hao Wang, Wei-Li Yang, Jin-Kui Yang
OBJECTIVES: Cathepsin L (CTSL) is a promising therapeutic target for metabolic disorders and COVID-19. However, there are still no clinically available CTSL inhibitors. Our objective is to develop an approach for the discovery of potential reversible covalent CTSL inhibitors. METHODS: The authors combined Chemprop, a deep learning-based strategy, and the Schrödinger CovDock algorithm to identify potential CTSL inhibitors. First, they used Chemprop to train a deep learning model capable of predicting whether a molecule would inhibit the activity of CTSL and performed predictions on ZINC20 in-stock librarie (~9...
March 2023: Expert Opinion on Drug Discovery
https://read.qxmd.com/read/36806002/effects-of-cathepsin-k-inhibitors-on-dentin-erosion-an-in-vitro-study
#8
JOURNAL ARTICLE
Yi-Ying Chen, Xiu-Jiao Lin, Zhi-Cen Lu, Annette Wiegand, Hao Yu
Cathepsin K (catK) modulates the degradation of dentin collagen. This study aimed to evaluate the effects of catK inhibitors on dentin erosion. Dentin beams were eroded (4 times/d for 5 days) and immersed in deionized water (negative control), 0.1 <sc>M</sc> NaCl, 0.3 <sc>M</sc> NaCl, 0.5 <sc>M</sc> NaCl, or 1 μ<sc>m</sc> odanacatib (each n = 16) for 30 min after each erosive challenge. Erosive dentin loss (EDL) and demineralized organic matrix (DOM) thickness were evaluated profilometrically...
2023: Caries Research
https://read.qxmd.com/read/36608993/effect-of-odanacatib-on-the-release-of-ntx-amino-terminal-telopeptide-from-lps-contaminated-type-i-dentin-collagen
#9
JOURNAL ARTICLE
Arwa Bafail, Karina Midori Mori Carneiro, Anil Kishen, Anuradha Prakki
OBJECTIVE: To evaluated the Odanacatib inhibitor treatment on lipopolysaccharide (LPS) contamination effect on cathepsin-K mediated dentin degradation by analysis of type I collagen C- and N-termini telopeptides. METHODS: Pulverized and disks of human dentin were demineralized and LPS contaminated, or stored in deionized water (DW) for 12 h. Samples were challenged with lactic acid (LA). Aliquots of dentin powder were treated with 1 mL Odanacatib or stored in DW for 30 min...
January 4, 2023: Dental Materials
https://read.qxmd.com/read/36386169/a-multifunctional-drug-consisting-of-tetracycline-conjugated-with-odanacatib-for-efficient-periodontitis-therapy
#10
JOURNAL ARTICLE
Dengke Li, Wuyang Zhang, Weiliang Ye, Yuan Liu, Yuan Li, Yiming Wang, Bingqing Shi, Xueni Zheng, Ying An, Zhen Ma, Kaijin Hu, Hongzhi Zhou, Yang Xue
The treatment of periodontitis can be very challenging due to its complex etiologies. A new pharmacologic strategy entitled "host-modulation therapy," has been introduced to improve periodontal treatment outcomes. Supposedly, a multifunctional drug with the potential for bacterial infection prevention, host-response modulation and bone healing promotion would be a promising option for periodontitis therapy, but related studies remain substantially lacking. In this study, we successfully conjugated tetracycline with odanacatib (a selective inhibitor of cathepsin K) to construct a multifunctional drug (TC-ODN)...
2022: Frontiers in Pharmacology
https://read.qxmd.com/read/36276721/the-impact-of-medication-on-osseointegration-and-implant-anchorage-in-bone-determined-using-removal-torque-a-review
#11
JOURNAL ARTICLE
Martina Jolic, Sonali Sharma, Anders Palmquist, Furqan A Shah
Permanently anchored metal implants are frequently used in dental, craniomaxillofacial, and orthopaedic rehabilitation. The success of such therapies is owed to the phenomenon of osseointegration-the direct connection between the living bone and the implant. The extent of biomechanical anchorage (i.e., physical interlocking between the implant and bone) can be assessed with removal torque (RTQ) measurement. Implant anchorage is strongly influenced by underlying bone quality, involving physicochemical and biological properties such as composition and structural organisation of extracellular matrix, extent of micro-damage, and bone turnover...
October 2022: Heliyon
https://read.qxmd.com/read/36145649/varied-bulk-powder-properties-of-micro-sized-api-within-size-specifications-as-a-result-of-particle-engineering-methods
#12
JOURNAL ARTICLE
Zijian Wang, Marina Solomos, Stephanus Axnanda, Chienhung Chen, Margaret Figus, Luke Schenck, Changquan Calvin Sun
Micronized particles are commonly used to improve the content uniformity (CU), dissolution performance, and bioavailability of active pharmaceutical ingredients (API). Different particle engineering routes have been developed to prepare micron-sized API in a specific size range to deliver desirable biopharmaceutical performance. However, such API particles still risk varying bulk powder properties critical to successful manufacturing of quality drug products due to different particle shapes, size distribution, and surface energetics, arising from the anisotropy of API crystals...
September 8, 2022: Pharmaceutics
https://read.qxmd.com/read/36065588/diabetes-mellitus-and-the-benefit-of-antiresorptive-therapy-on-fracture-risk
#13
JOURNAL ARTICLE
Richard Eastell, Eric Vittinghoff, Li-Yung Lui, Susan K Ewing, Ann V Schwartz, Douglas C Bauer, Dennis M Black, Mary L Bouxsein
Type 2 diabetes (T2D) is associated with increased risk of fractures. However, it is unclear whether current osteoporosis treatments reduce fractures in individuals with diabetes. The aim of the study was to determine whether presence of T2D influences the efficacy of antiresorptive treatment for osteoporosis using the Foundation for the National Institutes of Health (FNIH)-American Society for Bone and Mineral Research (ASBMR)-Study to Advance Bone Mineral Density (BMD) as a Regulatory Endpoint (SABRE) cohort, which includes individual patient data from randomized trials of osteoporosis therapies...
November 2022: Journal of Bone and Mineral Research
https://read.qxmd.com/read/36044342/assessment-of-reversibility-for-covalent-cysteine-protease-inhibitors-using-quantum-mechanics-molecular-mechanics-free-energy-surfaces
#14
JOURNAL ARTICLE
Alberto M Dos Santos, Amanda Ruslana Santana Oliveira, Clauber H S da Costa, Peter W Kenny, Carlos A Montanari, Jaldyr de Jesus G Varela, Jerônimo Lameira
We have used molecular dynamics (MD) simulations with hybrid quantum mechanics/molecular mechanics (QM/MM) potentials to investigate the reaction mechanism for covalent inhibition of cathepsin K and assess the reversibility of inhibition. The computed free energy profiles suggest that a nucleophilic attack by the catalytic cysteine on the inhibitor warhead and proton transfer from the catalytic histidine occur in a concerted manner. The results indicate that the reaction is more strongly exergonic for the alkyne-based inhibitors, which bind irreversibly to cathepsin K, than for the nitrile-based inhibitor odanacatib, which binds reversibly...
August 31, 2022: Journal of Chemical Information and Modeling
https://read.qxmd.com/read/35711006/effects-of-odanacatib-on-bone-turnover-markers-in-osteoporotic-postmenopausal-women-a-post-hoc-analysis-of-the-loft-study
#15
JOURNAL ARTICLE
L T Duong, S Clark, M Pickarski, H Giezek, D Cohn, R Massaad, S A Stoch
This post hoc analysis and modeling study examined the mechanism of action of odanacatib using a statistical model to explain sCTx response in ODN-treated patients as a function of other bone-turnover biomarkers that, with other observed biomarker changes, showed that odanacatib persistently inhibited osteoclastic bone removal activity without preventing osteoclastogenesis. INTRODUCTION: Odanacatib (ODN) is an oral selective cathepsin K (CatK) inhibitor, previously in development for osteoporosis treatment...
June 17, 2022: Osteoporosis International
https://read.qxmd.com/read/35584569/bap1-phosphorylation-mediated-sp1-stabilization-plays-a-critical-role-in-cathepsin-k-inhibition-induced-c-terminal-p53-dependent-bax-upregulation
#16
JOURNAL ARTICLE
Seung Un Seo, Seon Min Woo, Seul Gi Lee, Min Yeong Kim, Hyun Shik Lee, Yung Hyun Choi, Sang Hyun Kim, Young-Chae Chang, Kyoung-Jin Min, Taeg Kyu Kwon
Cathepsin K inhibitor (odanacatib; ODN) and cathepsin K knockdown (siRNA) enhance oxaliplatin-induced apoptosis through p53-dependent Bax upregulation. However, its underlying mechanisms remain unclear. In this study, we elucidated the mechanism behind enhancement of oxaliplatin-induced apoptosis by ODN. We also investigated the molecular mechanisms of ODN-induced Bax upregulation. Here, we demonstrated that ODN-induced Bax upregulation required p53, but it was independent of p53 transcriptional activity. Various mutants of the DNA-binding domain of p53 induced Bax upregulation in ODN-treated cells...
May 13, 2022: Redox Biology
https://read.qxmd.com/read/35342038/metabolic-bone-diseases-and-new-drug-developments
#17
REVIEW
Vijayakumar Natesan, Sung-Jin Kim
Metabolic bone diseases are serious health issues worldwide, since several million individuals over the age of 50 are at risk of bone damage and should be worried about their bone health. One in every two women and one in every four men will break a bone during their lifetime due to a metabolic bone disease. Early detection, raising bone health awareness, and maintaining a balanced healthy diet may reduce the risk of skeletal fractures caused by metabolic bone diseases. This review compiles information on the most common metabolic bone diseases (osteoporosis, primary hyperparathyroidism, osteomalacia, and fluorosis disease) seen in the global population, including their symptoms, mechanisms, and causes, as well as discussing their prevention and the development of new drugs for treatment...
July 1, 2022: Biomolecules & Therapeutics
https://read.qxmd.com/read/35137661/a-patent-review-on-cathepsin-k-inhibitors-to-treat-osteoporosis-2011-2021
#18
JOURNAL ARTICLE
Fernanda R Rocho, Vinícius Bonatto, Rafael F Lameiro, Jerônimo Lameira, Andrei Leitão, Carlos A Montanari
INTRODUCTION: Cathepsin K (CatK) is a lysosomal cysteine protease and the predominant cathepsin expressed in osteoclasts, where it degrades the bone matrix. Hence, CatK is an attractive therapeutic target related to diseases characterized by bone resorption, like osteoporosis. AREAS COVERED: This review summarizes the patent literature from 2011 to 2021 on CatK inhibitors and their potential use as new treatments for osteoporosis. The inhibitors were classified by their warheads, with the most explored nitrile-based inhibitors...
March 10, 2022: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/35036057/loss-of-full-length-pumilio-1-abrogates-mirna-221-induced-gene-p27-silencing-mediated-cell-proliferation-in-the-heart
#19
JOURNAL ARTICLE
Yue Zhou, Denise YuEn Ng, Arthur Mark Richards, Peipei Wang
Upregulated expression of microRNA (miR)-221 is associated with downregulation of p27 and subsequent increased cell proliferation in a variety of human cancers. It is unknown whether miR-221 mimics could trigger neoplastic cellular proliferation. In vitro , we demonstrated miR-221 significantly downregulates the expression of P27 and increases proliferation of H9c2 and cardiac fibroblasts. The knockdown of PUM1 but not PUM2 abolished such effects by miR-221, as verified by RT-qPCR and western blot, direct binding of p27 3' UTR by luciferase reporter assay and cell proliferation by Ki67...
March 8, 2022: Molecular Therapy. Nucleic Acids
https://read.qxmd.com/read/34785775/inhibition-of-cathepsin-k-sensitizes-oxaliplatin-induced-apoptotic-cell-death-by-bax-upregulation-through-otub1-mediated-p53-stabilization-in-vitro-and-in-vivo
#20
JOURNAL ARTICLE
Seung Un Seo, Seon Min Woo, Shin Kim, Jong-Wook Park, Hyun-Shik Lee, Young-Seuk Bae, Sang Hyun Kim, Seung-Soon Im, Ji Hae Seo, Kyoung-Jin Min, Taeg Kyu Kwon
Cathepsin K is highly expressed in various types of cancers. However, the effect of cathepsin K inhibition in cancer cells is not well characterized. Here, cathepsin K inhibitor (odanacatib; ODN) and knockdown of cathepsin K (siRNA) enhanced oxaliplatin-induced apoptosis in multiple cancer cells through Bax upregulation. Bax knockdown significantly inhibited the combined ODN and oxaliplatin treatment-induced apoptotic cell death. Stabilization of p53 by ODN played a critical role in upregulating Bax expression at the transcriptional level...
November 16, 2021: Oncogene
keyword
keyword
97774
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.